Skip Nav Destination
Issues
1 May 1999
ISSN 1078-0432
EISSN 1557-3265
Minireview
Advances in Brief
Phase I Study of 90Y-labeled B72.3 Intraperitoneal Administration in Patients with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity1
Michael G. Rosenblum; Claire F. Verschraegen; James L. Murray; Andrzej P. Kudelka; Jacalyn Gano; Lawrence Cheung; John J. Kavanagh
Clinical Trials
Locoregional Regulatory Peptide Receptor Targeting with the Diffusible Somatostatin Analogue 90Y-Labeled DOTA0-d-Phe1-Tyr3-octreotide (DOTATOC): A Pilot Study in Human Gliomas1
Adrian Merlo; Oliver Hausmann; Morten Wasner; Philipp Steiner; Andreas Otte; Eduard Jermann; Peter Freitag; Jean-Claude Reubi; Jan Müller-Brand; Otmar Gratzl; Helmut R. Mäcke
Efficacy and Safety of Simultaneous Immunomagnetic CD34+ Cell Selection and Breast Cancer Cell Purging in Peripheral Blood Progenitor Cell Samples Used for Hematopoietic Rescue after High-Dose Therapy1
Michael Mohr; Eva Hilgenfeld; Thomas Fietz; Berthold Hoppe; Michael Koenigsmann; Marianne Hoffmann; Wolfgang U. Knauf; Uwe Cassens; Walter Sibrowski; Joachim Kienast; Eckhard Thiel; Wolfgang E. Berdel
Molecular Oncology, Markers, Clinical Correlates
Experimental Therapeutics, Preclinical Pharmacology
Cancer Biology, Immunology, Cytokines
Autologous High-Killing Cytotoxic T Lymphocytes against Human Lung Cancer Are Induced Using Interleukin (IL)-1β, IL-2, IL-4, and IL-6: Possible Involvement of Dendritic Cells1
Yasuo Saijo; Xin Hong; Masashi Tanaka; Ryushi Tazawa; Shu Qin Liu; Kaoru Saijo; Tadao Ohno; Kaoru Koike; Kazuhiro Ohkuda; Ken Satoh; Toshihiro Nukiwa
Mechanisms of Apoptosis in T Cells from Patients with Renal Cell Carcinoma1
Robert G. Uzzo; Patricia Rayman; Vladimir Kolenko; Peter E. Clark; Tracy Bloom; A. Michelle Ward; Luis Molto; Charles Tannenbaum; Lydia J. Worford; Ronald Bukowski; Raymond Tubbs; Eric D. Hsi; Neil H. Bander; Andrew C. Novick; James H. Finke
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.